POSTER PRESENTATIONS

CLINICAL
OUTCOMES
STUDIES
 
COST
STUDIES

Arthritis

Cancer

Cardiovascular Disease

Diabetes

Infectious Diseases

Mental Health

Respiratory Disorders

Other Diseases and Disorders
QUALITY
OF LIFE
& UTILITY
STUDIES

 

Arthritis and Neurological Diseases

Cancer

Cardiovascular Disease

Diabetes

Mental Health

Respiratory Disorders

Other Diseases and Disorders

Methods
HEALTHCARE
POLICY STUDIES
 
METHODS AND
CONCEPT PAPERS
 
 
CLINICAL OUTCOMES STUDIES

PCOS1:
COMMUNITY-BASED OUTCOMES RESEARCH INITIATIVE FOR CHRONIC RENAL DISEASES

Sasahara E1, Iida E1, Tajima Y1, Terajima T1, Ogawa M2, Yoshida H3, Irie Y3, Yamagata S1, Satoh N1, Ueda S1, 1Chiba University Graduate School of Pharmaceutical Sciences, Chiba-shi, Chiba, Japan; 2Chiba University Graduate School of Medicine, Chiba-shi, Chiba, Japan; 3Sanai Memorial Hospital, Chiba-shi, Chiba, Japan


PCOS5:
EVIDENCE ON THE RELATIVE EFFECTIVENESS OF OLANZAPINE AND RISPERIDONE OVER TIME


Davey P, FitzGerald P, Birinyi-Strachan L, M-TAG Pty Ltd, Chatswood, NSW, Australia


PCOS10:
EVALUATION OF CLOPIDOGREL USE IN MEDICAL PATIENTS OF A GENERAL TEACHING HOSPITAL


Lee VW, Lau CC, Lau CS, Mo CL, Chan TY, The Chinese University of Hong Kong, Shatin, Hong Kong
 
 

COST STUDIES



COST STUDIES - CARDIOVASCULAR DISEASE


PCSCD1:
COST-EFFECTIVENESS OF STATINS AFTER REVISION OF NCEP ATPIII: COMPARISON BETWEEN ATORVASTATIN AND SIMVASTATIN


Cheng CW, You JH, The Chinese University of Hong Kong, Hong Kong, China

PCSCD3:
COST-MINIMIZATION ANALYSIS IN HYPERTENSION WITH CORONARY ARTERY DISEASE BASED ON JAPAN MULTICENTER INVESTIGATION FOR CARDIOVASCULAR DISEASE DATA: NIFEDIPINE RETARD VERSUS ACE-INHIBITOR


Fujikawa K1, Yui Y2, Kawai C2, Jmic B3, 1Bayer Yakuhin Ltd, Osaka, Osaka, Japan; 2Kyoto University Hospital, Kyoto, Kyoto, Japan; 3JMIC-B Investigators, Kyoto, Kyoto, Japan



COST STUDIES -
INFECTIOUS DISEASES


PCSID10:
A COST ANALYSIS OF CHRONIC HEPATITIS B INFECTION & ITS ASSOCIATED COMPLICATIONS IN SINGAPORE


Ong SC, Lim SG, Yeoh KG, Li SC, National University of Singapore, Singapore, Singapore


COST STUDIES -
MENTAL HEALTH


 
COST STUDIES
-
RESPIRATORY DISORDERS



COST STUDIES - OTHER DISEASES AND DISORDERS


 

QUALITY OF LIFE & UTILITY STUDIES

QUALITY OF LIFE & UTILITY STUDIES - ARTHRITIS AND NEUROLOGICAL DISEASES




QUALITY OF LIFE & UTILITY STUDIES - CANCER




QUALITY OF LIFE STUDIES - CARDIOVASCULAR DISEASE




QUALITY OF LIFE STUDIES - DIABETES




QUALITY OF LIFE & UTILITY STUDIES - MENTAL HEALTH



QUALITY OF LIFE & UTILITY STUDIES - RESPIRATORY DISORDERS



QUALITY OF LIFE STUDIES - OTHER DISEASES AND DISORDERS




QUALITY OF LIFE STUDIES - METHODS

 
HEALTHCARE POLICY STUDIES

PHP8:
FACTORS CONSIDERED IN PHARMACEUTICAL REIMBURSEMENT IN AUSTRALIA: A ROLE FOR THE RULE OF RESCUE?


PHP8(2)
Wonder M, De Abreu Lourenco R, Novartis Pharmaceuticals Australia Pty Ltd, North Ryde, NSW, Australia
 

PHP9:
MANDATORY INCLUSION OF PHARMACOECONOMICS IN DRUG FUNDING - LESSONS FROM THE AUSTRALIAN APPROACH 1993 – 2003

Davey P, Lees M, Makino K, M-TAG Pty Ltd, Chatswood, NSW, Australia





METHODS AND CONCEPT PAPERS

 

1st Asia-Pacific Conference Main Page
 

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2008 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.
 
Website design by Eagle Systems USA, Inc.